The study aims at gathering additional data on the safety and effectiveness of using intravenous administration of the drugs Ca-DTPA/Zn-DTPA to remove the heavy metal gadolinium from the bodies of patients who have retained it and developed symptoms of Gadolinium Deposition Disease following an MRI in which a gadolinium-containing contrast agent was utilized. The outcome data will include measures of symptom relief after as many as six paired Calcium-DTPA/Zinc-DTPA chelation treatments. The study also aims at gathering additional data before and after DTPA treatment regarding levels of certain cytokines in the patients' blood that have been reported to be abnormally elevated in patients with retained gadolinium.

Start Date11 Apr 2023

Sponsor / Collaborator

Stanford University

NCT04138056 / CompletedPhase 2

A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine

The purpose of this study is to evaluate the safety, ability of GSK Biologicals' investigational RSV maternal vaccine (RSVPreF3) to generate an immune response and the degree to which the vaccine can cause side effects, when administered alone and in combination with Boostrix vaccine in healthy non-pregnant women 18-45 years of age. Two dose levels of RSVPreF3 and 2 Boostrix [Diphtheria, Tetanus and acellular Pertussis (dTpa) vaccine] formulations (US and ex-US) will be evaluated. A 2nd dose of RSVPreF3 will be administered in an extension of the study to assess the durability of the immune response after the first dose vaccination, and to assess the safety and immunogenicity following a second dose vaccination of the RSVPreF3 maternal vaccine.

Start Date05 Nov 2019

Sponsor / Collaborator

GSK Plc

NCT02450279 / TerminatedNot Applicable

Scintigraphic Comparison of Lung Deposition With Two Nebulizers During Invasive Mechanical Ventilation

Many devices are available for nebulising drug solution during invasive mechanical ventilation. Vibrating-mesh nebulizers ensure the highest lung deposition output. A recent international survey on aerosol therapy during mechanical ventilation (Ehrmann et al. 2013) reported that jet nebulizers remained the mostly used.
The aim of this study is to compare lung deposition of a radiolabeled administered with both nebulizers during invasive mechanical ventilation by planar scintigraphy.

Start Date01 Mar 2016

Sponsor / Collaborator

Cliniques Universitaires Saint-Luc

100 Clinical Results associated with Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

100 Translational Medicine associated with Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

100 Patents (Medical) associated with Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

4,208

Literatures (Medical) associated with Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

01 Mar 2024·Carbohydrate polymers

Rapid self-healing carboxymethyl chitosan/hyaluronic acid hydrogels with injectable ability for drug delivery

Article

Author: Zhang, Fengjiao ; Feng, Yao ; Cui, Shuyuan ; Coseri, Sergiu ; Jing, Xiaokai ; Zhang, Sufeng

In this study, the quaternized carboxymethyl chitosan (QCMCS), oxidized hyaluronic acid (OHA), 3,3'-dithiobis-(propionohydrazide) (DTP) were used as raw materials for the synthesis of hydrogels with excellent properties as carriers for drug release. The hydrogels were prepared by a simple "one-pot" method without external stimuli on the basis of interactions between formed dynamic covalent bonds (imine bonds, acylhydrazone bonds, disulfide bonds) and hydrogen bonds. The hydrogels had rapid self-healing properties, with a self-healing rate of 96 % after 30 min, as well as good pH responsiveness and excellent cytocompatibility (up to 98 % cell survival). The compressive stress of the hydrogels reached 423 kPa. Moreover, a representative drug (acetylsalicylic acid) demonstrated sustained release in the hydrogels (>72 h). The drug release behaviour was shown to be consistent with the Fick diffusion mechanism by kinetic modelling. Collectively, the findings demonstrate that the QCMCS + OHA + DTP injectable self-healing hydrogels are a potential material for the construction of pH-controlled drug delivery platforms.

01 Feb 2024·Nuclear medicine communications

A comparative study on the quality of in vivo labeled red blood cell radionuclide ventriculography images employing different freeze-dried reagents

Article

Author: Felix, Renata C. M. ; Guimarães, Tiago T. ; Pujatti, Priscilla B. ; Gomes, Maria Luisa ; Cardoso, Marcella A. S. ; dos Santos, João Paulo G.

Radionuclide ventriculography or Multi Gated Acquisition (MUGA) employing [99mTc]Technetium red blood cell (RBC) labeling is considered the gold standard for cardiotoxicity assessments in cancer patients undergoing chemotherapy. This in-vivo RBC labeling technique involves the reduction of [99mTc]Technetium by the stannous chloride present in freeze-dried reagent kits, with the pyrophosphate kit (PYP) being the most employed for this purpose. The literature, however, describes diethylenetriaminepentaacetic acid (DTPA) as an alternative to PYP, although a lack of comparative data from MUGA images between both reagents is noted. A retrospective cross-sectional observational study was conducted at the Brazilian National Cancer Institute Nuclear Medicine Service concerning 80 randomized MUGA images, 20 obtained employing DTPA between 2020 and 2023 and 60 obtained employing PYP between 2017 and 2020, applying the mean count per pixel (ct/pixel) and heart background (C/F) ratios as quality image indicators. Although the heart ct/pixel ratio was statistically lower in the DTPA images compared with PYP (P = 0.02), the C/F ratio was statistically similar when comparing both radiopharmaceuticals (P = 0.697). A semi-quantitative analysis of MUGA images obtained with DTPA and PYP indicates similar image quality, supporting the use of DTPA as an alternative to PYP without compromising diagnostic interpretations.

01 Feb 2024·Regulatory toxicology and pharmacology : RTP

Zinc deficiency induced by the chelating agent DTPA and its regulatory interpretation for developmental toxicity classification

Review

Author: Bade, Steffen ; Hindle, Stuart ; Arts, Josje H E

Aminocarboxylic acid (ethylenediamine-based) chelating agents such as DTPA are widely used in a variety of products and processes. Recently, DTPA was classified in the European Union as a developmental toxicant CLP Category 1B. However, according to the CLP regulation (CLP, 2008) classification as a developmental toxicant requires a chemical to possess an intrinsic, specific property to do so. This paper provides overwhelming evidence that shows the developmental toxicity only seen at a sustained high dose of 1000 mg DTPA/kg bw/day in rats during pregnancy is mediated by zinc depletion which leads to non-specific secondary effects associated with zinc deficiency. Therefore, based on the CLP regulation itself, viz. the lack of a specific, intrinsic property, supported by significant differences in zinc kinetics and physiology between pregnant rats and pregnant women, DTPA should not be classified as a developmental toxicant. Moreover, classification for developmental toxicity resulting from zinc deficiency, and only observed at high doses, would not increase protection of human health; instead, it will only lead to onerous and disproportionate restrictions being placed on the use of this substance.

News (Medical) associated with Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

11 Jun 2024

·www.prnewswire.com

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 | DelveInsight

The rise in demand for anti-radiation drugs is mainly driven by several factors. These include the growing occurrence of side effects linked to cancer screening methods, heightened risks of exposure to radiological or nuclear emergencies, and the increasing focus of nuclear-capable nations on safeguarding against radiation. These trends are expected to fuel the expansion of the anti-radiation drugs market from 2024 to 2030. LAS VEGAS, June 11, 2024 /PRNewswire/ -- DelveInsight's Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation drugs companies' market shares, challenges, anti-radiation drugs market drivers, barriers, trends, and key market anti-radiation drugs companies in the market. Key Takeaways from the Anti-Radiation Drugs Market Report As per DelveInsight estimates, North America is anticipated to dominate the global anti-radiation drugs market during the forecast period. In the compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category had a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide. Notable anti-radiation drugs companies such as Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and several others, are currently operating in the anti-radiation drugs market. In September 2023, the U.S. Department of Defense awarded Edina-based Humanetics a USD 20 million contract to develop a pill that prevents radiation damage in military members and first responders affected by events such as nuclear accidents, warfare, and dirty bombs. In May 2023, the first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body, testing the safety, tolerability, and processing in the body of escalating doses of the investigational drug product HOPO 14-1 was initiated in healthy adults. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, was funding the Phase 1 trial, which was sponsored and conducted by SRI International of Menlo Park, California. In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy). To read more about the latest highlights related to the anti-radiation drugs market, get a snapshot of the key highlights entailed in the Global Anti-Radiation Drugs Market Report Anti-Radiation Drugs Overview Anti-radiation drugs are pharmaceutical compounds designed to mitigate the damaging effects of radiation exposure on the human body. These drugs work by either scavenging free radicals generated by radiation or by enhancing the repair mechanisms of cells damaged by radiation. One class of anti-radiation drugs includes radioprotectors, which are administered before radiation exposure to prevent or reduce its harmful effects. Another class, known as radiomitigators, is given after exposure to alleviate the severity of radiation-induced damage. These drugs hold significant promise in scenarios such as nuclear accidents, medical radiation therapy, and space travel, where the risk of radiation exposure is a concern. Research into anti-radiation drugs is ongoing, with scientists continually striving to improve their efficacy and minimize side effects. Some compounds under investigation show potential not only in protecting against acute radiation sickness but also in mitigating long-term effects such as cancer development. As our understanding of radiation biology advances, coupled with advancements in drug development technologies, the prospects for more effective and accessible anti-radiation drugs continue to brighten, offering hope for safer environments in radiation-prone situations. Anti-Radiation Drugs Market Insights In 2023, North America dominated the anti-radiation drugs market, primarily due to several factors contributing to growth. These include a substantial patient population afflicted with various illnesses like cancer, increasing numbers of diagnostic procedures, and governmental initiatives aimed at public health in the region. This trend is expected to continue from 2024 to 2030. The prevalence of cancer in the United States, for example, drives a significant demand for anti-radiation drugs. Statistics from the American Cancer Society projected around 2 million new cancer cases in the United States in 2024, leading to heightened demand for these drugs to support cancer diagnostic procedures. Additionally, the US benefits from a strong focus on clinical research and the presence of leading pharmaceutical companies, further bolstering the market for anti-radiation drugs. Moreover, in 2022, the US Department of Health and Human Services (HHS) allocated USD 290 million for the purchase of Nplate, a drug produced by Amgen USA Inc., intended to treat radiation sickness in the event of a nuclear emergency. This investment reflects ongoing efforts to enhance preparedness for radiological and nuclear emergencies and underscores the commitment to saving lives in such scenarios. To know more about why North America is leading the market growth in the anti-radiation drugs market, get a snapshot of the Anti-Radiation Drugs Market Outlook Anti-Radiation Drugs Market Dynamics The market dynamics of anti-radiation drugs are driven by a complex interplay of factors ranging from technological advancements to geopolitical events and regulatory frameworks. One of the primary drivers is the increasing threat of radiation exposure from various sources such as nuclear accidents, medical procedures, and potential radiological terrorism. This heightened awareness has propelled research and development efforts to create effective anti-radiation drugs that can mitigate the harmful effects of radiation exposure. Moreover, the growing prevalence of cancer and the widespread use of radiation therapy as a treatment modality has further fueled the demand for anti-radiation drugs. As more individuals undergo radiation-based treatments, there is a parallel need for medications that can protect healthy tissues and organs from the damaging effects of ionizing radiation. The competitive landscape of the anti-radiation drugs market is characterized by both established pharmaceutical companies and innovative startups vying for market share. Established players often leverage their resources and expertise to develop and commercialize new anti-radiation drugs, while startups focus on disruptive technologies and novel approaches to address unmet needs in radiation protection. Government initiatives and regulatory frameworks also play a crucial role in shaping the market dynamics of anti-radiation drugs. Regulatory agencies set standards for safety, efficacy, and quality assurance, which impact the development, approval, and commercialization of these medications. Additionally, government investments in research and development, as well as funding for procurement and stockpiling of anti-radiation drugs for emergency preparedness, influence market dynamics. Overall, the anti-radiation drugs market is characterized by a dynamic landscape driven by technological innovation, healthcare trends, regulatory factors, and geopolitical considerations. As the threat of radiation exposure continues to evolve, so too will the demand for effective anti-radiation drugs, driving further growth and innovation in this important sector of the pharmaceutical industry. Get a sneak peek at the anti-radiation drugs market dynamics @ Anti-Radiation Drugs Market Dynamics Analysis Anti-Radiation Drugs Market Assessment Anti-Radiation Drugs Market Segmentation Anti-Radiation Drugs Market Segmentation By Compound: Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and Others Anti-Radiation Drugs Market Segmentation By Indication: Acute Radiation Syndrome, Cancer Treatment, and Others Anti-Radiation Drugs Market Segmentation By Radiation Type: Ionizing Radiations and Non-Ionizing Radiations Anti-Radiation Drugs Market Segmentation By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others Anti-Radiation Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the anti-radiation drugs market are set to emerge as the trendsetter explore @ Anti-Radiation Drugs Companies Table of Contents Interested in knowing the anti-radiation drugs market by 2030? Click to get a snapshot of the Anti-Radiation Drugs Market Trends Related Reports Cancer Biomarkers Market Cancer Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer biomarkers companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., among others. Cancer Therapy Market Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others. Oncology Drugs Market Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, BeiGene, among others. Liquid Biopsy in Cancer Diagnostics Market Liquid Biopsy in Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key liquid biopsy in cancer diagnostics companies, including Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

Radiation Therapy

22 Jan 2024

·www.medicaldesignandoutsourcing.com

Potential bioelectric applications of organic mixed ionic–electronic conductors

Researchers in Korea say they found a way to potentially accelerate the development of high-performance organic electrochemical transistor devices with tunable transient responses. Organic mixed ionic-electronic conductors (OMIECs) offer potential bioelectric applications. Researchers at the Gwangju Institute of Science and Technology (GIST) used the transistors as platforms for testing the molecular orientation and ion injection directionality-dependent transient properties of OMIECs. Potential applications for OMIECs include computing and bio-fuel cells in addition to bioelectronics. The researchers say that, to ensure a wider acceptance of these materials, there remains a need to diversify their properties and develop techniques for application-specific OMIEC tailoring. They cite a “severe” lack of research on the molecular orientation-dependent transient behaviors of such conductors. The team at GIST, consisting of researchers from both Korea and the UK, set out to bridge the gap in understanding there. Professor Myung-Han Yoon from the GIST School of Materials Science and Engineering led the researchers. They explored the transient behaviors of OMIECs governed by variations in molecular orientation with the help of an organic electrochemical transistor (OECT). “OECTs are known to mimic the computing mechanisms of neurons and synapses in spiking neural networks (SNNs) and are thus considered promising,” said Yoon. “To aid the growing interest in exploring the dynamic behaviors of OECTs at the frequency domain, we focused on an aspect that is often overlooked. We decided to investigate the correlation between backbone planarity-dependent molecular orientation and transient OECT characteristics.” First, they synthesized two new 1,4-dithienylphenylene (DTP)-based OMEICs, DTP-2T and DTP-P, with co-monomer units, 2,2’-bithiophene and phenylene, respectively. According to GIST, the polymers comprised the same ionic and electronic properties. However, by manipulating the polymer backbone planarity, the researchers controlled the dominant molecular orientation of the mixed conductor system. This polymer then successfully helped to fabricate OECT devices. The team found that the polymers showed similar electrochemical properties despite having different molecular orientations. They then changed the ion injection direction when observing a certain current/voltage during the analysis. In the analysis, the researchers saw that ion injection relative to the molecular orientation affected the length of the ion drift pathway. This, in turn, resulted in peculiar transient responses in OECT devices. The team believes it could use its research to facilitate the design and development of advanced organic mixed conductor materials for biomolecular and biosignal sensors. “OECT-based SNN architectures are anticipated to replace current computing systems in the future by increasing computation speed and reducing energy consumption,” Yoon said. “Our findings are expected to facilitate the realization of SNN-based computing systems soon.”

13 Dec 2022

·www.prnewswire.com

Anti-radiation Drugs Market to Reach US$ 9.6 Bn by 2031, TMR Study

Rise in investment in R&D by pharma and biotech companies for the development of effective drugs for acute radiation syndrome or ARS propels market growth Increase in efforts by pharmaceutical companies to develop innovative radiopharmaceutical products augments industry development WILMINGTON, Del., Dec. 13, 2022 /PRNewswire/ -- The global anti-radiation drugs market was valued at US$ 3.4 Bn in 2021 and is anticipated to grow at a CAGR of 9.9% from 2022 to 2031. Increase in demand for drugs, such as Prussian Blue, Diethylenetriamine pentaacetate or DTPA, and potassium iodide or KI, to block the concentration and absorption of radioactive iodide in the human thyroid gland propels market growth. Moreover, the threat of nuclear disaster looms over humanity owing to the increasing number of nuclear weapons and warheads in the world. Therefore, rise in efforts by countries to be prepared for nuclear or radioactive disasters by developing radiation countermeasures is augmenting market development. Quick Delivery Available | Buy this Premium Research Report – Anti-radiation Drugs Market - Key Findings of the Report Rise in Prevalence of Acute Radiation Syndrome: As per market research, the acute radiation syndrome (ARS) segment dominated the industry in 2021. ARS, at present, is considered the most crucial and challenging aspect regarding public health and well-being in a likely case of radiological or nuclear incidence. Apart from ARS, increasing incidence of cancer is boosting market growth. Growing Demand for Potassium Iodide Products: Based on type of compound, the potassium iodide (KI) segment led the global market in 2021. Tablets and drug formulations manufactured using potassium iodide compounds offer excellent protection against certain cases of exposure to harmful radiations. Furthermore, being a highly soluble form of iodine, KI compounds are the widely used active pharmaceutical ingredients in the radiopharmaceuticals industry. Apart from this, owing to its recorded effectiveness and safe nature in treating patients suffering from radiation exposure in the Chernobyl disaster, KI compounds are considered to be safest in treating ARS, even in small children. Anti-radiation Drugs Market – Growth Drivers Surge in incidence of cancer propels demand for anti-radiation drugs Rise in prevalence of acute radiation syndrome or ARS Increase in concerns pertaining to usage of nuclear weapons in global conflict is anticipated to augment market growth in the next few years Ask for References – Anti-radiation Drugs Market - Key Players Key players and manufacturers assessed in this market research are Arco Pharmaceuticals LLC, Cellphire, Inc., Darnitsa, Humanetics Corporation, Myelo Therapeutics GmbH, Pluri, Inc., Anbex Inc., BTG Pharmaceuticals LLC, Chrysalis BioTherapeutics, Inc., Enzychem Lifesciences Corporation, Mission Pharmacal Company, and Partner Therapeutics. The global market is consolidated, with the presence of a relatively small number of leading and tier 1 players. These players adopt growth strategies, such as merger & acquisition, and launch of new products, to increase market share. Manufacturers are also focused on increasing research & development initiatives and projects in order to design, develop, and test new compounds and drug formulations that display enhanced anti-radiation properties. Anti-radiation Drugs Market - Regional Growth Assessment North America is anticipated to lead the global industry in the next decade. Key factors driving the market in the region are increase in the number of radiation treatment facilities and rise in investment by stakeholders in the anti-radiation medical devices industry. Furthermore, growing participation and significant role played by the U.S. Government for developing biologically produced medical countermeasures for acute radiation syndrome are expected to propel the market demand. Anti-radiation Drugs Market: Segmentation Anti-radiation Drugs Market, by Compound Potassium Iodide (KI) Prussian Blue DTPA (Diethylenetriamine Pentaacetate) Others Anti-radiation Drugs Market, by Application Acute Radiation Syndrome (ARS) Cancer Treatment Radiation Exposure Others Anti-radiation Drugs Market, by Distribution Channel Hospital Pharmacies Retail Pharmacies Others Anti-radiation Drugs Market, by Region North America Latin America Europe Asia Pacific Middle East & Africa Make an Enquiry Before Buying – Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Research Reports by Transparency Market Research: Halal and Kosher Empty Capsules Market: Halal and Kosher Empty Capsules Market is anticipated to reach more than US$ 2.9 Bn by the end of 2031 and to grow at a CAGR of 8.0% from 2022 to 2031. Alzheimer's Disease Biomarkers Market: Alzheimer's Disease Biomarkers Marketis anticipated to grow at a CAGR of 7.3% from 2022 to 2031 and reach more than US$ 1.7 Bn by the end of 2031. Animal Drug Compounding Market: The global animal drug compounding market is anticipated to be reach more than US$ 2.4 Bn by the end of 2031 at a CAGR of 7.4% between 2022 and 2031. Primary Progressive Multiple Sclerosis Treatment Market: Primary Progressive Multiple Sclerosis Treatment Market is projected to advance at a CAGR of 14.7% from 2022 to 2031 ad reach more than US$ 3.2 Bn by the end of 2031. Fusion Inhibitors Market: Fusion Inhibitors Market is projected to advance at a CAGR of 14.2% from 2022 to 2031 and reach more than US$ 7.2 Bn by 2031. Rare Kidney Diseases Treatment Market: Rare Kidney Diseases Treatment Market is projected to grow at a CAGR of 5.8% from 2022 to 2031 and reach more than US$ 4.6 Bn by the end of 2031. Asthma Treatment Market: Asthma Treatment Market is projected to grow at a CAGR of 3.7% from 2022 to 2031 and reach more than US$ 34.5 Bn by the end of 2031. About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - Contact Nikhil Sawlani Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Blog: Email: [email protected] Logo: SOURCE Transparency Market Research

Radiation Therapy

100 Deals associated with Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14007

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diagnostic agents	JP	PDRadiopharma, Inc.	22 May 1979

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 1	-	University of California San Diego	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ERS2021	Not Applicable	Scleroderma, Diffuse KL-6 \| SP-D	58	Tc99m – DTPA aerosols	fdmjaqljpp(zdxehxbtjp) = zkgpdlstdx elofwoogxh (fbrjuypxuh, 25.7)	Positive	05 Sep 2021
NCT01982123 (CTgov)	Not Applicable	Lung Cancer	12	SPECT/CT+Technetium Tc-99m DTPA	wpyervasmq(oncgbiasbz) = zanuzwangg vxhzohsbom (kymmdaizab, thsjcoqnye - xtszuvevuk) View more	-	13 Dec 2018
AUA2017	Not Applicable	-	699	DIETHYLENE TRIAMINE PENTA-ACETIC ACID (DTPA) (Group 1)	jnhjsfbehe(cdqscqdmdc) = wqzdniwpbo qhdnlbnoop (ceumwaivvs ) View more	-	01 Apr 2017
AUA2017	Not Applicable	-	699	DIETHYLENE TRIAMINE PENTA-ACETIC ACID (DTPA) (Group 2)	jnhjsfbehe(cdqscqdmdc) = oubqbjtiye qhdnlbnoop (ceumwaivvs ) View more	-	01 Apr 2017
Pubmed \| Clin Chest Med	Not Applicable	Pulmonary Cystic Fibrosis	-	DTPA (CF subjects)	ogsgypqkcs(nnzpxqutoa) = crwgnvsfrv hmkoznruuz (znrzfdrkjt )	-	01 Apr 2010
Pubmed \| Clin Chest Med	Not Applicable	Pulmonary Cystic Fibrosis	-	DTPA (Control subjects)	ogsgypqkcs(nnzpxqutoa) = ciqgvvtrwi hmkoznruuz (znrzfdrkjt )	-	01 Apr 2010

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis